Updated: 24th June 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder & CEO)
ISO 14971 and the Risk Management of Medical Devices
Risk management is one of the most important aspects of medical device development and regulatory compliance. Manufacturers must identify potential hazards, evaluate risks, implement controls, and continually monitor device performance throughout the product lifecycle to ensure patient safety.
ISO 14971 is the internationally recognised standard for the application of risk management to medical devices. It provides a systematic framework for identifying, evaluating, controlling and monitoring risks associated with medical devices throughout their lifecycle. The standard is recognised globally and is used to support compliance with regulations including EU MDR 2017/745, EU IVDR 2017/746, UK MDR 2002 and FDA requirements.
This guide explains the requirements of ISO 14971, the risk management process, risk management documentation, regulatory expectations and practical implementation considerations for medical device manufacturers.
Why ISO 14971 Matters for Medical Device Manufacturers
The primary objective of ISO 14971 is to ensure that risks associated with a medical device are reduced as far as possible while maintaining the intended clinical benefits of the device.
Medical device manufacturers must demonstrate that:
- Hazards have been identified
- Risks have been analysed and evaluated
- Appropriate risk controls have been implemented
- Residual risks are acceptable
- Benefits outweigh any remaining risks
- Risks continue to be monitored after market release
Risk management is not a one-time activity. It continues throughout the entire product lifecycle and forms a key component of regulatory compliance.
Further Reading: ISO 14971 Risk Management
What Is ISO 14971?
ISO 14971 is an international standard that establishes a framework for the application of risk management to medical devices.
The standard requires manufacturers to systematically:
- Identify hazards
- Estimate associated risks
- Evaluate risk acceptability
- Implement risk control measures
- Evaluate residual risks
- Monitor risks throughout the product lifecycle
The standard applies to all medical devices regardless of classification, technology or intended purpose.
The ISO 14971 Risk Management Process
The ISO 14971 process follows a structured lifecycle approach:
- Risk Management Planning
- Risk Identification
- Risk Analysis
- Risk Evaluation
- Risk Control
- Residual Risk Evaluation
- Risk-Benefit Analysis
- Production and Post-Production Activities
Each stage should be documented within the Risk Management File.
ISO 14971 Risk Management Plan
The Risk Management Plan defines how risk management activities will be performed for a specific device.
The plan should include:
- Scope of activities
- Responsibilities
- Risk acceptability criteria
- Risk analysis methods
- Verification activities
- Post-market monitoring activities
- Review requirements
The plan serves as the foundation for all risk management activities.
Hazard Identification and Foreseeable Risks
Manufacturers must identify all known and foreseeable hazards associated with the device.
Potential hazards may include:
- Biological hazards
- Electrical hazards
- Mechanical hazards
- Software failures
- Usability-related hazards
- Cybersecurity risks
- Manufacturing defects
- Labelling and IFU deficiencies
Both normal use and reasonably foreseeable misuse must be considered.
Understanding Hazards, Hazardous Situations and Harm
A common area of confusion is the distinction between:
Hazard
A potential source of harm
Hazardous Situation
Circumstances in which people, property or the environment are exposed to a hazard.
Harm
Physical injury, damage to health or damage to property.
Understanding these relationships is essential when constructing a risk analysis.
Risk Analysis
Once hazards have been identified, risks must be analysed.
Risk analysis typically considers:
- Severity of harm
- Probability of occurrence
Many manufacturers use tools such as:
- Failure Modes and Effects Analysis (FMEA)
- Fault Tree Analysis (FTA)
- Hazard Analysis
- Preliminary Hazard Analysis (PHA)
Risk analysis should be evidence-based and supported by available data, including clinical evidence, testing data, historical complaint information and post-market surveillance findings where available.
The objective is to establish a clear understanding of the potential impact of each identified hazard and determine whether further risk controls are required.
Risk Evaluation
Following risk analysis, manufacturers evaluate whether identified risks are acceptable according to predefined risk acceptability criteria.
Risk evaluation helps determine:
- Acceptable risks
- Risks requiring additional controls
- Risks requiring redesign or further mitigation
These criteria should be defined within the Risk Management Plan and applied consistently throughout the assessment process.
Only risks meeting predefined acceptability criteria may proceed without additional action.
Risk Control Measures
When risks are not acceptable, manufacturers must implement risk control measures.
ISO 14971 establishes a hierarchy of risk controls:
Inherently Safe Design
The preferred approach is to eliminate hazards through design changes wherever possible.
Examples include:
- Removing hazardous components
- Reducing operating temperatures
- Simplifying user interfaces
- Redesigning device architecture
Protective Measures
Where hazards cannot be eliminated, protective measures may be implemented.
Examples include:
- Physical guards
- Software controls
- Alarm systems
- Interlocks
- Automatic shut-off functions
Information for Safety
Warnings, precautions and instructions should only be used when risks cannot be adequately reduced through design or protective measures.
Examples include:
- Device labelling
- Instructions for Use (IFU)
- Safety warnings
- Training requirements
Manufacturers should always prioritise higher-level controls before relying on information for safety.
Residual Risk Evaluation
After implementing risk controls, manufacturers must evaluate residual risks.
Residual risks are the risks that remain after mitigation measures have been applied.
Residual risks should:
- Be documented
- Be assessed for acceptability
- Be communicated where appropriate
- Be periodically reviewed throughout the device lifecycle
Where residual risks remain, manufacturers must determine whether they are acceptable in relation to the intended clinical benefits of the device.
Risk-Benefit Analysis
In some cases residual risks cannot be reduced further.
Manufacturers must then demonstrate that the clinical benefits of using the device outweigh the remaining risks.
This assessment should be supported by:
- Clinical evaluation data
- Performance studies
- Scientific literature
- Post-market surveillance data
- Clinical experience
Risk-benefit analysis is particularly important for higher-risk medical devices where some level of residual risk may be unavoidable.
The Risk Management File
ISO 14971 requires manufacturers to establish and maintain a Risk Management File.
The Risk Management File serves as the central repository for all risk management documentation associated with a device.
Typical contents include:
- Risk Management Plan
- Hazard Analysis
- Risk Assessments
- FMEA Documentation
- Risk Control Records
- Verification Activities
- Risk-Benefit Assessments
- Post-Market Data
- Risk Management Reports
The file should be maintained throughout the device lifecycle and updated whenever new information becomes available.
The Risk Management File is frequently reviewed during regulatory audits and technical documentation assessments.
Production and Post-Production Information
Risk management does not end once a device has been released to market.
Manufacturers must establish processes to collect and review production and post-production information.
This may include:
- Customer complaints
- Vigilance reports
- Adverse incidents
- Corrective and Preventive Actions (CAPA)
- Manufacturing nonconformities
- Post-Market Surveillance (PMS) data
- Post-Market Clinical Follow-up (PMCF) data
- Competitor safety information
New risks identified through these activities should be assessed and incorporated into the Risk Management File.
Risk management should remain an active process throughout the entire lifecycle of the device.
ISO 14971 and ISO 13485
ISO 14971 and ISO 13485 work closely together.
ISO 13485 establishes the Quality Management System requirements, while ISO 14971 provides the framework for managing product risks.
Risk management activities influence numerous aspects of a Quality Management System, including:
- Design and development
- Supplier controls
- Purchasing activities
- CAPA processes
- Post-market surveillance
- Management review
- Change management
Manufacturers implementing ISO 13485 should ensure that risk management principles are integrated throughout their QMS.
For a more detailed explanation, read our guide on ISO 14971 and ISO 13485: How Risk and Quality Intersect.
ISO/TR 24971 Guidance
ISO/TR 24971 provides supplementary guidance on implementing ISO 14971.
While ISO 14971 establishes the requirements, ISO/TR 24971 provides practical explanations and examples to assist manufacturers with implementation.
The guidance covers topics such as:
- Hazard identification
- Risk estimation
- Risk evaluation
- Benefit-risk analysis
- Software risk management
- Production and post-production monitoring
Many manufacturers use ISO/TR 24971 alongside ISO 14971 to strengthen their risk management processes and ensure consistent application of the standard.
ISO 14971 and Regulatory Compliance
Compliance with ISO 14971 supports medical device regulatory requirements worldwide.
The standard is commonly used to demonstrate conformity with:
- EU MDR 2017/745
- EU IVDR 2017/746
- UK MDR 2002
- FDA Quality System requirements
- Health Canada requirements
- Other international regulatory frameworks
Risk management forms a fundamental part of demonstrating device safety and performance and is embedded throughout modern medical device regulations.
Manufacturers should ensure that risk management activities are fully integrated into their technical documentation and quality management systems.
Summary
ISO 14971 provides a structured framework for identifying, evaluating, controlling and monitoring risks throughout the lifecycle of a medical device.
By implementing effective risk management processes and maintaining a comprehensive Risk Management File, manufacturers can demonstrate regulatory compliance, support patient safety and ensure the continued effectiveness of their medical devices.
Risk management should not be viewed as a regulatory exercise but as an ongoing process that contributes directly to device safety, performance and continual improvement.
How Can Patient Guard Help?
Patient Guard supports manufacturers with:
- ISO 14971 implementation
- Risk Management Files
- FMEA development
- MDR and IVDR compliance
- Clinical risk-benefit assessments
- Post-market risk management
- Technical documentation support
- Quality Management System integration
Our team can help manufacturers establish robust risk management processes that meet the requirements of ISO 14971 and applicable medical device regulations.
Contact Patient Guard to discuss your medical device risk management requirements.
Frequently Asked Questions About ISO 14971 and the Risk Management of Medical Devices
The purpose of ISO 14971 in medical devices is to provide a systematic framework for identifying, evaluating, and controlling risks throughout a device’s lifecycle, ensuring that risks are reduced to acceptable levels while demonstrating compliance with regulatory safety requirements.
ISO 14971 helps with risk management in compliance with EU MDR by providing a harmonized framework to identify, evaluate, and control risks, ensuring that medical devices meet safety and performance requirements while demonstrating that benefits outweigh risks as required by EU MDR.
The key steps in the ISO 14971 risk management process are:
- Risk Analysis: Identify hazards, estimate risks, and evaluate risk acceptability.
- Risk Control: Implement measures to reduce risks and reassess residual risks.
- Evaluation of Overall Residual Risk: Ensure all remaining risks are acceptable and benefits outweigh risks.
- Post-Market Surveillance: Continuously monitor and update the risk management file throughout the device lifecycle.
Patient Guards Recent Posts
Predetermined Change Control Plans (PCCPs): The Future of Agile Compliance for Medical Device Software
Learn how PCCPs help medical device software manufacturers manage updates, support AI systems, and enable agile compliance under evolving MDR and UKCA frameworks.
The AI Act Omnibus Explained: What the 2026 EU Rules Mean for Medical Device and IVD Manufacturers
Discover how the EU AI Act Omnibus affects AI medical devices and IVD manufacturers. Learn about the No Duplication principle, transparency rules, key 2026 and 2028 deadlines, and how MDR and IVDR compliance are converging with AI regulation.
Post-Deadline Reality Check: I’ve Submitted My IVDR Class C – Now What?
Submitted your IVDR Class C application? Learn what happens next, common causes of delays, review timelines, and why the September 2026 contract deadline is critical for maintaining EU market access.
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
